Recent studies suggest that OPG may be a new therapeutic agent for bone loss associated with metabolic diseases such as osteoporosis and rheumatoid arthritis (Bucay et al, 1998; Kong et al, 1999; Kostenuik et al, 2001; Redlich et al, 2002). This evidence concerns the gene TNFRSF11B and Other metabolic disease.